Zenas Yiu
@zznyiu.bsky.social
@officialuom.bsky.social #Dermatology #RxEpi
MRC Clinician Scientist
NICE Technology Appraisal D Committee member
MRC Clinician Scientist
NICE Technology Appraisal D Committee member
PhD opportunity @ UoM
Multi-omics analysis for treatment response in #psoriasis #PsA using national datasets
Competitive studentship through MRC-DTP scheme
Supervised by James Bluett, Magnus Rattray, Ali Al-Janabi, and myself
Deadline 8th Nov
www.findaphd.com/phd...
Multi-omics analysis for treatment response in #psoriasis #PsA using national datasets
Competitive studentship through MRC-DTP scheme
Supervised by James Bluett, Magnus Rattray, Ali Al-Janabi, and myself
Deadline 8th Nov
www.findaphd.com/phd...
October 8, 2025 at 1:28 PM
PhD opportunity @ UoM
Multi-omics analysis for treatment response in #psoriasis #PsA using national datasets
Competitive studentship through MRC-DTP scheme
Supervised by James Bluett, Magnus Rattray, Ali Al-Janabi, and myself
Deadline 8th Nov
www.findaphd.com/phd...
Multi-omics analysis for treatment response in #psoriasis #PsA using national datasets
Competitive studentship through MRC-DTP scheme
Supervised by James Bluett, Magnus Rattray, Ali Al-Janabi, and myself
Deadline 8th Nov
www.findaphd.com/phd...
PhD opportunity @ UoM - long-term outcomes and use of antibiotics in #hidradenitis using the CPRD
Competitive studentship funded by the MRC-DTP scheme
Supervised by myself, Darren Ashcroft, Stevie Shoop-Worrall, and Tjeerd Van Staa
Deadline 8th Nov
www.findaphd.com/phd...
Competitive studentship funded by the MRC-DTP scheme
Supervised by myself, Darren Ashcroft, Stevie Shoop-Worrall, and Tjeerd Van Staa
Deadline 8th Nov
www.findaphd.com/phd...
October 8, 2025 at 1:25 PM
PhD opportunity @ UoM - long-term outcomes and use of antibiotics in #hidradenitis using the CPRD
Competitive studentship funded by the MRC-DTP scheme
Supervised by myself, Darren Ashcroft, Stevie Shoop-Worrall, and Tjeerd Van Staa
Deadline 8th Nov
www.findaphd.com/phd...
Competitive studentship funded by the MRC-DTP scheme
Supervised by myself, Darren Ashcroft, Stevie Shoop-Worrall, and Tjeerd Van Staa
Deadline 8th Nov
www.findaphd.com/phd...
Another bivalent biologic presented at #EADV2025, this time for #atopicdermatitis #eczema - IL-13 and IL17A/F inhibitor Galvokimig in a small phase IIA RCT
potentially very helpful for Asian Th17 AD phenotype or patients at risk of phenotypic switch
potentially very helpful for Asian Th17 AD phenotype or patients at risk of phenotypic switch
September 19, 2025 at 7:23 PM
Another bivalent biologic presented at #EADV2025, this time for #atopicdermatitis #eczema - IL-13 and IL17A/F inhibitor Galvokimig in a small phase IIA RCT
potentially very helpful for Asian Th17 AD phenotype or patients at risk of phenotypic switch
potentially very helpful for Asian Th17 AD phenotype or patients at risk of phenotypic switch
The third study presented at #EADV2025 from Novartis using spatial transcriptomics to look at #hidradenitis
Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion
IMO more data to suggest a need to hit multiple targets
Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion
IMO more data to suggest a need to hit multiple targets
September 19, 2025 at 11:54 AM
The third study presented at #EADV2025 from Novartis using spatial transcriptomics to look at #hidradenitis
Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion
IMO more data to suggest a need to hit multiple targets
Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion
IMO more data to suggest a need to hit multiple targets
Exciting to hear a new bivalent drug that targets TNF and OX40L Brivekimig for the treatment of #hidradenitis - we likely need more drugs that have multiple targets to treat this difficult disease
Looking forward to the explanatory phase III RCTs
#EADV2025
Looking forward to the explanatory phase III RCTs
#EADV2025
September 19, 2025 at 11:43 AM
Exciting to hear a new bivalent drug that targets TNF and OX40L Brivekimig for the treatment of #hidradenitis - we likely need more drugs that have multiple targets to treat this difficult disease
Looking forward to the explanatory phase III RCTs
#EADV2025
Looking forward to the explanatory phase III RCTs
#EADV2025
Probably the closest effort to precision medicine so far in dermatology presented by Michel Gillet - using nanostring measuring gene expression - to differentiate between skin diseases outside of morphology
#EADV2025
#EADV2025
September 19, 2025 at 11:31 AM
Probably the closest effort to precision medicine so far in dermatology presented by Michel Gillet - using nanostring measuring gene expression - to differentiate between skin diseases outside of morphology
#EADV2025
#EADV2025
Good and slower burning response from OX-40 inhibitor rocatinlimab for #atopicdermatitis - results from the phase III RCT ROCKET-SHUTTLE which allows concomitant topical steroids
#EADV2025
#EADV2025
September 18, 2025 at 1:15 PM
Good and slower burning response from OX-40 inhibitor rocatinlimab for #atopicdermatitis - results from the phase III RCT ROCKET-SHUTTLE which allows concomitant topical steroids
#EADV2025
#EADV2025
Really interesting new mechanism of action to target T-regulatory cells in #atopicdermatitis for Rezpeg
seems safe and effective in this phase 2b RCT but again this choice of as observed open label extension arm makes it difficult to interpret longer term effect
#EADV2025
seems safe and effective in this phase 2b RCT but again this choice of as observed open label extension arm makes it difficult to interpret longer term effect
#EADV2025
September 18, 2025 at 1:00 PM
Really interesting new mechanism of action to target T-regulatory cells in #atopicdermatitis for Rezpeg
seems safe and effective in this phase 2b RCT but again this choice of as observed open label extension arm makes it difficult to interpret longer term effect
#EADV2025
seems safe and effective in this phase 2b RCT but again this choice of as observed open label extension arm makes it difficult to interpret longer term effect
#EADV2025
Izokibep shows moderate response, again around 13% delta mark for HiSCR75 at week 12, for #hidradenitis
Not convinced more single target biologics are what we need
#EADV2025
Not convinced more single target biologics are what we need
#EADV2025
September 17, 2025 at 1:17 PM
Izokibep shows moderate response, again around 13% delta mark for HiSCR75 at week 12, for #hidradenitis
Not convinced more single target biologics are what we need
#EADV2025
Not convinced more single target biologics are what we need
#EADV2025
Good to see phase III data for povorcitinib for #hidradenitis. Delta for primary endpoint of HiSCR50 slightly disappointing around 10-12%, but good to see draining tunnels resolving better.
Why use as observed imputation for extension, which is biased?
#EADV2025
Why use as observed imputation for extension, which is biased?
#EADV2025
September 17, 2025 at 1:05 PM
Good to see phase III data for povorcitinib for #hidradenitis. Delta for primary endpoint of HiSCR50 slightly disappointing around 10-12%, but good to see draining tunnels resolving better.
Why use as observed imputation for extension, which is biased?
#EADV2025
Why use as observed imputation for extension, which is biased?
#EADV2025
Do antibiotics have a direct anti-inflammatory activity in #hidradenitis? Some data to show they do, especially clindamycin, from a 3D seboskin model study from Germany
#EADV2025
#EADV2025
September 17, 2025 at 12:02 PM
Do antibiotics have a direct anti-inflammatory activity in #hidradenitis? Some data to show they do, especially clindamycin, from a 3D seboskin model study from Germany
#EADV2025
#EADV2025
Two interesting spatial transcriptomics studies in #hidradenitis highlighting abnormal epithelialisation and the complex immunological pathogenesis respectively in the EHSF session
#EADV2025
#EADV2025
September 17, 2025 at 11:59 AM
Two interesting spatial transcriptomics studies in #hidradenitis highlighting abnormal epithelialisation and the complex immunological pathogenesis respectively in the EHSF session
#EADV2025
#EADV2025
Great to hear the new classification for epidermal differentiation disorders from Edel O’Toole, which follows a logical naming convention starting with the gene.
#EADV2025
#EADV2025
September 17, 2025 at 10:37 AM
Great to hear the new classification for epidermal differentiation disorders from Edel O’Toole, which follows a logical naming convention starting with the gene.
#EADV2025
#EADV2025
Great to hear from Henry Lim in the 1st plenary of the Global Chinese Dermatology Summit that ustekinumab and adalimumab are part of the WHO list of essential medicines!
#GCDS2025 #psoriasis
#GCDS2025 #psoriasis
September 6, 2025 at 1:16 AM
Great to hear from Henry Lim in the 1st plenary of the Global Chinese Dermatology Summit that ustekinumab and adalimumab are part of the WHO list of essential medicines!
#GCDS2025 #psoriasis
#GCDS2025 #psoriasis
We have a great #PhD opportunity with a multi-disciplinary supervisory team to understand the impact of UV radiation on #eczema #atopicdermatitis using methods from epidemiology, wearables, data science, and behavioural science
Deadline 7/7/2025!
www.findaphd.com/phd...
Deadline 7/7/2025!
www.findaphd.com/phd...
June 19, 2025 at 12:28 PM
We have a great #PhD opportunity with a multi-disciplinary supervisory team to understand the impact of UV radiation on #eczema #atopicdermatitis using methods from epidemiology, wearables, data science, and behavioural science
Deadline 7/7/2025!
www.findaphd.com/phd...
Deadline 7/7/2025!
www.findaphd.com/phd...
Reposted by Zenas Yiu
Target emulation trial w/ data from British Dermatologists Biologics & Immunomodulators Register, studied 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). jamanetwork.com/journals/jam...
jamanetwork.com
June 5, 2025 at 6:02 PM
Target emulation trial w/ data from British Dermatologists Biologics & Immunomodulators Register, studied 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). jamanetwork.com/journals/jam...
Interested in making a difference for people with #psoriasis in the UK?
Apply for this @PsoriasisUK funded PhD with me, Binh Phan, Richard Warren, and Gabriel Rogers and use data from @BADBIR and trials to conduct cost-effectiveness analyses
www.findaphd.com/phd...
Apply for this @PsoriasisUK funded PhD with me, Binh Phan, Richard Warren, and Gabriel Rogers and use data from @BADBIR and trials to conduct cost-effectiveness analyses
www.findaphd.com/phd...
April 24, 2025 at 4:31 PM
Interested in making a difference for people with #psoriasis in the UK?
Apply for this @PsoriasisUK funded PhD with me, Binh Phan, Richard Warren, and Gabriel Rogers and use data from @BADBIR and trials to conduct cost-effectiveness analyses
www.findaphd.com/phd...
Apply for this @PsoriasisUK funded PhD with me, Binh Phan, Richard Warren, and Gabriel Rogers and use data from @BADBIR and trials to conduct cost-effectiveness analyses
www.findaphd.com/phd...
Honoured to present on evidence based care in #psoriasis alongside amazing speakers for alopecia areata, urticaria, CTCL, acne, and photoaging at the #AAD2025 yesterday.
Learnt a lot from all the speakers on the topics at hand as well as how to get complex messages across
Learnt a lot from all the speakers on the topics at hand as well as how to get complex messages across
March 11, 2025 at 1:16 PM
Honoured to present on evidence based care in #psoriasis alongside amazing speakers for alopecia areata, urticaria, CTCL, acne, and photoaging at the #AAD2025 yesterday.
Learnt a lot from all the speakers on the topics at hand as well as how to get complex messages across
Learnt a lot from all the speakers on the topics at hand as well as how to get complex messages across
Slow and steady response for rocatinlimab, OX40 receptor inhibitor for atopic dermatitis
Looks like it is quite targeted and safe in this phase III study - but if the thought is a slower response they probably needed to have a later primary outcome timepoint
#AAD2025
Looks like it is quite targeted and safe in this phase III study - but if the thought is a slower response they probably needed to have a later primary outcome timepoint
#AAD2025
March 8, 2025 at 7:18 PM
Slow and steady response for rocatinlimab, OX40 receptor inhibitor for atopic dermatitis
Looks like it is quite targeted and safe in this phase III study - but if the thought is a slower response they probably needed to have a later primary outcome timepoint
#AAD2025
Looks like it is quite targeted and safe in this phase III study - but if the thought is a slower response they probably needed to have a later primary outcome timepoint
#AAD2025
Icotrokinra showing high but slightly lower response rates compared to injectable IL23i for #psoriasis - nonetheless a very high effectiveness for an oral medication
#AAD2025
#AAD2025
March 8, 2025 at 4:41 PM
Icotrokinra showing high but slightly lower response rates compared to injectable IL23i for #psoriasis - nonetheless a very high effectiveness for an oral medication
#AAD2025
#AAD2025
Much needed study to look at the impact of dupilumab on itch in epidermolysis bullosa and ichthyosis
need a bigger study with a control arm but very promising!
#AAD2025
need a bigger study with a control arm but very promising!
#AAD2025
March 8, 2025 at 4:31 PM
Much needed study to look at the impact of dupilumab on itch in epidermolysis bullosa and ichthyosis
need a bigger study with a control arm but very promising!
#AAD2025
need a bigger study with a control arm but very promising!
#AAD2025
ESK-001 showing promise as a targeted inhibitor of TYK2 for psoriasis in a phase II trial - now for the phase III study to confirm findings for blinded primary outcome
#AAD2025
#AAD2025
March 8, 2025 at 4:18 PM
ESK-001 showing promise as a targeted inhibitor of TYK2 for psoriasis in a phase II trial - now for the phase III study to confirm findings for blinded primary outcome
#AAD2025
#AAD2025